These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 1964186)

  • 1. [Cisplatin and vinca alkaloid combination chemotherapy of advanced non-small-cell lung cancer in the aged].
    Teramoto S; Nagase T; Fukuchi Y; Ishida K; Yamaoka M; Matsuse T; Jo C; Orimo H
    Nihon Ronen Igakkai Zasshi; 1990 Nov; 27(6):680-6. PubMed ID: 1964186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cisplatin combination chemotherapy in advanced lung cancer in the aged].
    Nagase T; Fukuchi Y; Matsuse T; Marumo K; Yamaoka M; Suruda T; Homma S; Yoshikawa M; Orimo H
    Nihon Ronen Igakkai Zasshi; 1989 Jul; 26(4):329-33. PubMed ID: 2607673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Establishment of the standard regimen for non-small-cell lung cancer in Japan.
    Masuda N
    Oncology (Williston Park); 2001 Jan; 15(1 Suppl 1):13-8. PubMed ID: 11221016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized trial with mitomycin-C/ifosfamide versus mitomycin-C/vindesine versus cisplatin/etoposide in advanced non-small-cell lung cancer.
    Gatzemeier U; Heckmayr M; Hossfeld DK; Kaukel E; Koschel G; Neuhauss R
    Am J Clin Oncol; 1991 Oct; 14(5):405-11. PubMed ID: 1659174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I clinical trial of irinotecan (CPT-11), 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, and cisplatin in combination with fixed dose of vindesine in advanced non-small cell lung cancer.
    Shinkai T; Arioka H; Kunikane H; Eguchi K; Sasaki Y; Tamura T; Ohe Y; Oshita F; Nishio M; Karato A
    Cancer Res; 1994 May; 54(10):2636-42. PubMed ID: 8168091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comparative study on vindesine plus cisplatin treatment of advanced non-small cell lung cancer--three divided doses (35 mg/m2, day 1, 8, 15) and single dose (80 mg/m2, day 1) of cisplatin. Chiba Lung Cancer Study Group].
    Nagao K; Fujisawa T; Miyamoto T; Kikuchi N; Takizawa H; Satoh K; Yamagishi F; Yamaguchi T; Mizutani F; Nakano K
    Gan To Kagaku Ryoho; 1991 Mar; 18(3):425-30. PubMed ID: 1848421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of carboplatin, cisplatin, and vindesine in advanced non-small-cell lung cancer.
    Saito H; Shimokata K; Saka H; Yamamoto M; Ogasawara T; Nomura F; Sakai S; Iwata M; Murate T; Miyachi T
    Cancer Chemother Pharmacol; 1993; 33(2):154-6. PubMed ID: 8261575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Results of a randomized study comparing combination of navelbine-cisplatin to combination of vindesine-cisplatin and to navelbine alone in 612 patients with inoperable non-small cell lung cancer].
    Le Chevalier T; Brisgand D; Pujol JL; Douillard JY; Monnier A; Rivière A; Chomy P; Le Groumellec A; Ruffie P; Gottfried M; Gaspard MH; Chevreau C; Alberola V; Cigolari S; Besson F; Martinez A; Besenval M; Berthaud P; Tursz T
    Bull Cancer; 1996 May; 83(5):385-94. PubMed ID: 8680091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant vindesine, etoposide, and cisplatin for locally advanced non-small cell lung cancer. Final report of a phase 2 study.
    Vokes EE; Bitran JD; Hoffman PC; Ferguson MK; Weichselbaum RR; Golomb HM
    Chest; 1989 Jul; 96(1):110-3. PubMed ID: 2544349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Chemotherapy of non-small cell bronchial cancer with ifosfamide in combination with cisplatin, etoposide or vindesine].
    Drings P; Becker H; Bülzebruck H; Djawid N; Ruchalla E; Stiefel P; Tessen HW
    Onkologie; 1988; 11 Suppl 2():47-56. PubMed ID: 2851761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized trial in inoperable non-small-cell lung cancer: vindesine and cisplatin versus mitomycin, vindesine, and cisplatin versus etoposide and cisplatin alternating with vindesine and mitomycin.
    Fukuoka M; Masuda N; Furuse K; Negoro S; Takada M; Matsui K; Takifuji N; Kudoh S; Kawahara M; Ogawara M
    J Clin Oncol; 1991 Apr; 9(4):606-13. PubMed ID: 1648597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotherapy of advanced non-small-cell lung cancer: a randomized trial of three cis-platin-based chemotherapy regimens.
    Hainsworth JD; Johnson DH; Hande KR; Greco FA
    Am J Clin Oncol; 1989 Aug; 12(4):345-9. PubMed ID: 2547305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A randomized study of navelbine compared to navelbine and cisplatin compared to vindesine and cisplatin in the treatment of inoperable non-small-cell lung carcinoma. The results of a European multicenter study including 612 patients].
    González Larriba JL; Alberola V; Lianes P; Panizo A; Carrato A; Muñoz Quintana A; Cardenal F; Gracia JM; Moyano A; Díaz-Rubio E
    Rev Clin Esp; 1994 Nov; 194(11):953-9. PubMed ID: 7846351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. European experience with ifosfamide in non-small cell lung cancer.
    Drings P
    Semin Oncol; 1989 Feb; 16(1 Suppl 3):22-30. PubMed ID: 2539645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized study of two vindesine plus cisplatin-containing regimens with the addition of mitomycin C or ifosfamide in patients with advanced non-small cell lung cancer.
    Rosell R; Abad-Esteve A; Moreno I; Barnadas A; Carles J; Fernandez C; Ribelles N; Culubret M
    Cancer; 1990 Apr; 65(8):1692-9. PubMed ID: 2156597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cisplatin and vindesine combination chemotherapy for non-small cell lung cancer: a randomized trial comparing two dosages of cisplatin.
    Shinkai T; Saijo N; Eguchi K; Sasaki Y; Tominaga K; Sakurai M; Suga J; Miyaoka H; Sano T; Keicho N
    Jpn J Cancer Res; 1986 Aug; 77(8):782-9. PubMed ID: 3019976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Chemotherapy of advanced non-small cell bronchial cancer with mitomycin C/ifosfamide versus mitomycin C/vindesine versus cisplatin/etoposide--a prospective randomized study].
    Gatzemeier U; Heckmayr M; Hossfeld DK; Kaukel E; Koschel G; Neuhauss R
    Pneumologie; 1990 Feb; 44 Suppl 1():258-60. PubMed ID: 2164194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective evaluation of the feasibility of cisplatin-based chemotherapy for elderly lung cancer patients with normal organ functions.
    Oshita F; Kurata T; Kasai T; Fakuda M; Yamamoto N; Ohe Y; Tamura T; Eguchi K; Shinkai T; Saijo N
    Jpn J Cancer Res; 1995 Dec; 86(12):1198-202. PubMed ID: 8636010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cisplatin, doxorubicin and vindesine in the treatment of advanced non-small cell lung cancer].
    Akiyama J; Sato A; Honda K; Chida K; Watanabe T; Okano H; Okano A; Taniguchi M; Genma H; Aoki H
    Gan To Kagaku Ryoho; 1991 Mar; 18(3):419-24. PubMed ID: 1848420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A three-arm trial of vinorelbine (Navelbine) plus cisplatin, vindesine plus cisplatin, and single-agent vinorelbine in the treatment of non-small cell lung cancer: an expanded analysis.
    Le Chevalier T; Pujol JL; Douillard JY; Alberola V; Monnier A; Riviere A; Lianes P; Chomy P; Cigolari S; Besson F
    Semin Oncol; 1994 Oct; 21(5 Suppl 10):28-33; discussion 33-4. PubMed ID: 7973766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.